Sharemaestro Newsreel

Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test

Pacira BioSciences (PCRX) has advanced its osteoarthritis gene therapy candidate, PCRX-201, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. The company's shares are currently trading at US$26.92, which is significantly below …

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences (PCRX) reported strong second-quarter 2026 results, beating analyst estimates for both earnings and revenues, driven by demand for Exparel, Zilretta, and iovera. Despite the strong performance, the company cut its 2026 sales outlook due to the divestiture of iovera, while maintaining other …

Aurora Cannabis Inc reports results for the quarter ended June 30 - Earnings Summary

Aurora Cannabis Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides an earnings summary for the company. Readers can access the full report through TradingView's news platform.

Organigram Global Sets August 11 Date for Q3 2026 Results

Organigram Global Inc. will release its financial results for the third quarter ended June 30, 2026, on August 11, 2026, before markets open. The company, Canada's largest cannabis firm, will also host a conference call and webcast to discuss its performance. Analysts currently rate …

Perrigo Company plc (PRGO) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Perrigo Company plc (PRGO) stock on the NYSE. It shows the current stock price of $13.12, a gain of $2.34 (21.69%), but notes that prices are delayed. The article also includes sections for analyst ratings, though …

Understanding the Setup: (ETON) and Scalable Risk

This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near-term sentiment but significant upside potential due to a lack of resistance above its current price. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and provides a …

Will Perrigo’s (PRGO) Q2 Profit Rebound and Reaffirmed Guidance Reshape Its Investment Narrative?

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue …

Organigram Global (OGI) to Release Earnings on Tuesday

Organigram Global (OGI) is scheduled to release its Q3 2026 earnings before market open on Tuesday, August 11th. Analysts anticipate a loss of $0.01 per share and revenue of approximately $68.2 million. The company's stock is currently trading near its 52-week low, and analyst …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results

[10-Q] PERRIGO Co plc Quarterly Earnings Report

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

TherapeuticsMD Inc. (TXMD) shares advanced 1.47% to $2.07 on Wednesday, outperforming a mixed trading session where the Dow Jones Industrial Average rose and the NASDAQ Composite Index fell. Despite the gain, the stock remains 29.83% below its 52-week high of $2.95, achieved on January …

Cronos Group Inc. stock falls Wednesday, underperforms market

Cronos Group Inc. (CRON) shares fell 3.20% on Wednesday, closing at $2.72. This decline occurred during a mixed trading session where the Dow Jones Industrial Average rose and the NASDAQ Composite Index fell, marking the stock's second consecutive day of losses.

Viatris faces earnings test as pipeline progress meets pricing pressure

Viatris Inc. is preparing to announce its second-quarter earnings, with analysts anticipating $0.61 EPS on $3.67 billion in revenue. Investors are keenly watching whether the company's recent pipeline successes, such as FDA acceptance for fast-acting meloxicam and positive Phase 3 results for VR-205, can …

LFCR Stock Price and Chart — NASDAQ:LFCR

Lifecore Biomedical, Inc. (LFCR) is a pharmaceutical company specializing in hyaluronan-based products. Its stock price is currently $5.01, with a market capitalization of $189.64 million. The company's recent earnings report showed declining revenue and profit year-over-year, but management reaffirmed 2026 guidance due to cost …

Perrigo Company Releases Q2 2026 Financial Results

Perrigo Company plc announced Q2 2026 financial results, exceeding Wall Street expectations for earnings per share despite a decline in sales. The company reported adjusted EPS of $0.50, significantly above the $0.35 forecast, on revenue of $1.02 billion. Perrigo projects full-year 2026 adjusted earnings …

Aurora Sees Lower Losses in Q1 2027 as International Growth Offsets Domestic Decline

Aurora Cannabis Inc. reported lower net losses of $4 million in Q1 FY2027, despite a 9% year-over-year decline in net revenue to $67.6 million. This reduction in losses was primarily driven by strong international medical cannabis sales, which grew by 17% to $43.3 million, …

Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook

BioCryst Pharmaceuticals reported Q2 2026 earnings that surpassed Wall Street expectations, with adjusted earnings of $0.30 per share against an estimated $0.16, and revenue of $218.3 million compared to a forecast of $185.69 million. The company raised its full-year 2026 revenue guidance to $690 …

Alvotech (ALVO) Could Be 72% Undervalued Following FDA Inspection Closure

Alvotech (ALVO) stock is under focus after the FDA closed its May 2026 inspection with a Voluntary Action Indicated classification, leading to a recent 23.87% share price return over 7 days despite a year-to-date decline. Analysts suggest the stock is 72.2% undervalued, with a …

Collegium Pharmaceutical (COLL): Principal Global Investors discloses 5% equity stake

Principal Global Investors has filed a Schedule 13G, reporting a passive 5% equity stake in Collegium Pharmaceutical, Inc. The firm beneficially owns 1,632,360 shares of common stock with shared voting and dispositive power. Both companies' principal offices are noted, with Collegium Pharmaceutical in Stoughton, …

Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High Following Strong Earnings

Elanco Animal Health (NYSE:ELAN) shares reached a new 52-week high after reporting strong quarterly earnings of $0.34 EPS, surpassing estimates, with revenue rising 10.2% to $1.37 billion. The company provided Q3 and full-year 2026 EPS guidance, and analysts maintain a "Moderate Buy" rating with …

Cronos earnings on deck: Can cannabis upstart sustain Q1 surge?

Cronos Group Inc. is set to report its second-quarter earnings, with analysts anticipating a decline in EPS and a slight dip in revenue compared to a strong first quarter. Investors will be watching closely to see if the company can maintain its market-leading positions …

Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Hims & Hers Health, Inc. (HIMS) after the Federal Trade Commission (FTC) filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news on July …

Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview

Lifecore Biomedical Inc is anticipated to report a loss of 22 cents per share, according to an earnings preview. This forecast is based on information shared through TradingView News, indicating an upcoming financial announcement for the company.

Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Quarterly Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a quarterly loss of $0.20 per share, missing analyst estimates. The company closed its Apotex transaction for $100 million and declared a special dividend of $1.50 per share, pivoting to focus on its ifetroban development pipeline. Despite the strategic shift …

Aurora Cannabis Inc.

Aurora Cannabis Inc. announced its financial and operational results for the first quarter of 2027, which ended on June 30, 2026. Following this announcement, shares of Aurora Cannabis Inc. (T.ACB) saw a modest increase, trading up $0.03 at $3.94. This news provides investors with …

Aurora Cannabis Inc. (ACB) Q1 Earnings and Revenues Beat Estimates

Aurora Cannabis Inc. (ACB) reported Q1 earnings of $0.04 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.13 per share and beating revenue expectations. The company has consistently exceeded EPS and revenue estimates over the past year. Despite the positive …

Press Release: Elanco Animal Health Reports Second Quarter 2026 Results

Elanco Animal Health (ELAN) has reported its second-quarter 2026 results. The article also briefly mentions Unity Software (U.US) which reported fourth-quarter revenue of $609 million, exceeding estimates, despite a quarterly loss of 66 cents per share. Full details of the Elanco report are behind …

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Teknova has launched Build-Tek™, an AI-powered custom order configurator for complex reagent requests, expanding on its 2024 buffer configurator. This tool allows therapeutic and diagnostic developers to design custom products and submit quote requests in minutes, significantly reducing the time from weeks to days. …

Lifecore Biomedical, Inc. reports results for the quarter ended June 30 - Earnings Summary

Lifecore Biomedical, Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides an earnings summary for the company. Readers are encouraged to access the full report for detailed information.

Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say

Perrigo (PRGO) reported Q2 2026 revenue of $1.02 billion, a 3.2% decrease year-over-year, and an EPS of $0.50, down from $0.57 in the prior year. Despite the revenue decrease, the company surpassed Zacks Consensus Estimates for both revenue and EPS. Key metric performance, including …

Collegium Pharmaceutical earnings ahead after ADHD acquisition

Collegium Pharmaceutical is set to report second-quarter earnings, with analysts anticipating increased revenue and earnings per share following the acquisition of ADHD medication AZSTARYS. Investors will closely watch the performance of AZSTARYS and the company's legacy pain medication portfolio, as well as updates on …

Citius Oncology's LYMPHIR is in 42 institutions with near-universal coverage

Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares

Xeris Biopharma insider Beth Hecht sold 16,666 shares of XERS for $8.01 per share on August 3, 2026, totaling approximately $133,495. This

Kamada (KMDA) Expected to Post Quarterly Earnings on Wednesday